🔴 Taysha Gene Therapies is trading 5.7% down in pre-market — no clear catalyst identified

Taysha Gene Therapies is trading at $4.01, down 5.65% in pre-market on October 28; no verified company-specific announcement explains the decline.

• Search results surfaced an Astellas investment story, but the underlying agreement dates to 2022 and is not a new catalyst.
• The supplied major indexes were modestly higher. Trading volume and activity details were not provided, and the reason for the decline remains unclear.